休止期脱发与新型冠状病毒感染的相关性及诊疗研究进展

doi:10.35541/cjd.20230069

中华皮肤科杂志 ›› 2023, e20230069.doi: 10.35541/cjd.20230069

休止期脱发与新型冠状病毒感染的相关性及诊疗研究进展

张硕1 张韡2 徐丹1

¹昆明医科大学第一附属医院，昆明 650000；²中国医学科学院北京协和医学院皮肤病医院病理科，南京 210042

收稿日期:2023-02-13 修回日期:2023-05-10 发布日期:2023-07-12
通讯作者: 张韡；徐丹 E-mail:ifmtjoel@163.com; drxudan@126.com
基金资助:
中国医学科学院临床与转化医学研究基金（2020-I2M-C&T-B-091）；国家自然科学基金（82160598、81660518）；西藏自治区自然科学基金（XZ2021ZR-ZY12［Z］）

Associations of telogen effluvium with coronavirus disease 2019 and research progress in its diagnosis and treatment

Zhang Shuo¹, Zhang Wei², Xu Dan¹

¹First Affiliated Hospital of Kunming Medical University, Kunming 650000, China; ²Department of Pathology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2023-02-13 Revised:2023-05-10 Published:2023-07-12
Contact: Zhang Wei; Xu Dan E-mail:ifmtjoel@163.com; drxudan@126.com
Supported by:
CAMS Innovation Fund for Medical Sciences （2020-I2M-C&T-B-091）; National Natural Science Foundation of China （82160598, 81660518）; Natural Science Foundation of Tibet Autonomous Region （XZ2021ZR-ZY12［Z］）

摘要/Abstract

摘要： 【摘要】休止期脱发是新型冠状病毒感染后脱发的最常见类型。本文综述了新型冠状病毒与休止期脱发的相关性、发病机制及诊疗进展。压力剧增、机体免疫反应、药物治疗、基础疾病加重等因素诱发了新型冠状病毒感染后休止期脱发。

关键词: 秃发, 休止期脱发, 新型冠状病毒, 应激, 心理学

Abstract: 【Abstract】 Telogen effluvium is the most common type of hair loss after coronavirus disease 2019. This review summarizes the literature on associations between coronavirus disease 2019 and telogen effluvium, as well as pathogenesis, diagnosis and treatment of telogen effluvium secondary to coronavirus disease 2019. Sharply increased stress, the body′s immune response, medications, and exacerbation of underlying diseases may be the main precipitating factors for telogen effluvium secondary to coronavirus disease 2019.

Key words: Alopecia, Telogen effluvium, SARS-CoV-2, Stress, psychological

张硕张韡徐丹. 休止期脱发与新型冠状病毒感染的相关性及诊疗研究进展[J]. 中华皮肤科杂志, 2023,e20230069. doi:10.35541/cjd.20230069

Zhang Shuo, Zhang Wei, Xu Dan. Associations of telogen effluvium with coronavirus disease 2019 and research progress in its diagnosis and treatment[J]. Chinese Journal of Dermatology,2023,e20230069. doi:10.35541/cjd.20230069

参考文献 43

［1］	Ocampo⁃Garza SS, Vastarella M, Nappa P, et al. Telogen effluvium in the new SARS⁃CoV⁃2 era［J］. Int J Dermatol, 2021,60（7）:e265⁃e266. doi: 10.1111/ijd.15482.
［2］	Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars⁃Cov⁃2 infection: clinical aspects and our management experience［J］. Dermatol Ther, 2021,34（1）:e14547. doi: 10.1111/dth.14547.
［3］	Sharquie KE, Jabbar RI. COVID⁃19 infection is a major cause of acute telogen effluvium［J］. Ir J Med Sci, 2022,191（4）:1677⁃1681. doi: 10.1007/s11845⁃021⁃02754⁃5.
［4］	Amor K T, Rashid R M, Mirmirani P. Does D matter? The role of vitamin D in hair disorders and hair follicle cycling［J/OL］. Dermatol Online J, 2010,16（2）:3. doi:10.5070/D38s34p6b7.
［5］	Asghar F, Shamim N, Farooque U, et al. Telogen effluvium: a review of the literature［J］. Cureus, 2020,12（5）:e8320. doi: 10.7759/cureus.8320.
［6］	Grover C, Khurana A. Telogen effluvium［J］. Indian J Dermatol Venereol Leprol, 2013,79（5）:591⁃603. doi: 10.4103/0378⁃6323. 116731.
［7］	Olds H, Liu J, Luk K, et al. Telogen effluvium associated with COVID⁃19 infection［J］. Dermatol Ther, 2021,34（2）:e14761. doi: 10.1111/dth.14761.
［8］	Chularojanamontri L, Tuchinda P, Rujitharanawong C, et al. New⁃onset and exacerbated skin diseases after COVID⁃19 infection: a systematic review［J］. J Dermatol, 2022,49（11）:e419⁃e421. doi: 10.1111/1346⁃8138.16501.
［9］	Müller⁃Ramos P, Ianhez M, Silva de Castro CC, et al. Post⁃COVID⁃19 hair loss: prevalence and associated factors among 5 891 patients［J］. Int J Dermatol, 2022,61（5）:e162⁃e164. doi: 10.1111/ijd.16041.
［10］	Cline A, Kazemi A, Moy J, et al. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID⁃19［J］. J Am Acad Dermatol, 2021,84（3）:773⁃775. doi: 10.1016/j.jaad.2020.11.032.
［11］	Aksoy H, Yıldırım UM, Ergen P, et al. COVID⁃19 induced telogen effluvium［J］. Dermatol Ther, 2021,34（6）:e15175. doi: 10.1111/dth.15175.
［12］	Tammaro A, Adebanjo G, Parisella FR, et al. Hair and nail manifestations of COVID⁃19［J］. J Cosmet Dermatol, 2022,21（4）:1339⁃1346. doi: 10.1111/jocd.14774.
［13］	Garcovich S, Bersani FS, Chiricozzi A, et al. Mass quarantine measures in the time of COVID⁃19 pandemic: psychosocial implications for chronic skin conditions and a call for qualitative studies［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:e293⁃e294. doi: 10.1111/jdv.16535.
［14］	Rebora A. Telogen effluvium: a comprehensive review［J］. Clin Cosmet Investig Dermatol, 2019,12:583⁃590. doi: 10.2147/CCID.S200471.
［15］	Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID⁃19 emergency: psychological implications［J］. Dermatol Ther, 2020,33（4）:e13648. doi: 10.1111/dth.13648.
［16］	Moreno⁃Arrones OM, Lobato⁃Berezo A, Gomez⁃Zubiaur A, et al. SARS⁃CoV⁃2⁃induced telogen effluvium: a multicentric study［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:e181⁃e183. doi: 10.1111/jdv.17045.
［17］	Headington JT. Telogen effluvium. New concepts and review［J］. Arch Dermatol, 1993,129（3）:356⁃363. doi: 10.1001/archderm. 129.3.356.
［18］	Gentile P. Hair loss and telogen effluvium related to COVID⁃19: the potential implication of adipose⁃derived mesenchymal stem cells and platelet⁃rich plasma as regenerative strategies［J］. International Journal of Molecular Sciences, 2022,23（16）: 9116. doi: 10.3390/ijms23169116.
［19］	Tosti A, Misciali C, Bardazzi F, et al. Telogen effluvium due to recombinant interferon alpha⁃2b［J］. Dermatology, 1992,184（2）:124⁃125. doi: 10.1159/000247518.
［20］	Rossi A, Magri F, Sernicola A, et al. Telogen effluvium after SARS⁃CoV⁃2 infection: a series of cases and possible pathogenetic mechanisms［J］. Skin Appendage Disord, 2021,21（5）:1⁃5. doi: 10.1159/000517223.
［21］	Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post⁃COVID⁃19 manifestation［J］. J Med Virol, 2022,94（4）:1391⁃1401. doi: 10. 1002/jmv.27534.
［22］	Kato H, Kinoshita K, Saito N, et al. The effects of ischemia and hyperoxygenation on hair growth and cycle［J］. Organogenesis, 2020,16（3）:83⁃94. doi: 10.1080/15476278.2020.1794271.
［23］	Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID⁃19 acute respiratory distress syndrome［J］. J Thromb Haemost, 2020,18（7）:1747⁃1751. doi: 10.1111/jth.14854.
［24］	Connors JM, Levy JH. COVID⁃19 and its implications for thrombosis and anticoagulation［J］. Blood, 2020,135（23）:2033⁃2040. doi: 10.1182/blood.2020006000.
［25］	Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID⁃19 and cardiovascular disease［J］. Circulation, 2020,141（20）:1648⁃1655. doi: 10.1161/CIRCULATIONAHA.120.046941.
［26］	Almeida G, Arruda S, Marques E, et al. Presentation and management of cutaneous manifestations of COVID⁃19［J］. J Drugs Dermatol, 2021,20（1）:76⁃83. doi: 10.36849/JDD.5676.
［27］	Bongiovanni M, Chiesa E, Monforte Ad, et al. Hair loss in an HIV⁃1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART［J/OL］. Dermatol Online J, 2003,9（5）:28.
［28］	Watras MM, Patel JP, Arya R. Traditional anticoagulants and hair loss: a role for direct oral anticoagulants? A review of the literature［J］. Drugs Real World Outcomes, 2016,3（1）:1⁃6. doi: 10.1007/s40801⁃015⁃0056⁃z.
［29］	Borrás⁃Blasco J, Belda A, Rosique⁃Robles D, et al. Hair loss induced by lopinavir⁃ritonavir［J］. Pharmacotherapy, 2007,27（8）:1215⁃1218. doi: 10.1592/phco.27.8.1215.
［30］	Cline A, Jacobs AK, Fonseca M, et al. Race, ethnicity, and comorbidities are critical factors in the diagnosis of telogen effluvium during the COVID⁃19 pandemic［J］. J Am Acad Dermatol, 2021,85（1）:209⁃211. doi: 10.1016/j.jaad.2021.03.099.
［31］	Cheung EJ, Sink JR, English Iii JC. Vitamin and mineral deficiencies in patients with telogen effluvium: a retrospective cross⁃sectional study［J］. J Drugs Dermatol, 2016,15（10）:1235⁃1237.
［32］	Lee Y, Min P, Lee S, et al. Prevalence and duration of acute loss of smell or taste in COVID⁃19 patients［J］. J Korean Med Sci, 2020,35（18）:e174. doi: 10.3346/jkms.2020.35.e174.
［33］	Duntas LH, Jonklaas J. COVID⁃19 and thyroid diseases: a bidirectional impact［J］. J Endocr Soc, 2021,5（8）:bvab076. doi: 10.1210/jendso/bvab076.
［34］	Baldelli R, Nicastri E, Petrosillo N, et al. Thyroid dysfunction in COVID⁃19 patients［J］. J Endocrinol Invest, 2021,44（12）:2735⁃2739. doi: 10.1007/s40618⁃021⁃01599⁃0.
［35］	Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders［J］. Transl Pediatr, 2017,6（4）:300⁃312. doi: 10.21037/tp.2017.09.08.
［36］	Alessandrini A, Bruni F, Piraccini BM, et al. Common causes of hair loss ⁃ clinical manifestations, trichoscopy and therapy［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:629⁃640. doi: 10.1111/ jdv.17079.
［37］	Abrantes TF, Artounian KA, Falsey R, et al. Time of onset and duration of post⁃COVID⁃19 acute telogen effluvium［J］. J Am Acad Dermatol, 2021,85（4）:975⁃976. doi: 10.1016/j.jaad.2021. 07.021.
［38］	Trüeb RM, Dutra Rezende H, Gavazzoni Dias M. What can the hair tell us about COVID⁃19?［J］. Exp Dermatol, 2021,30（2）:288⁃290. doi: 10.1111/exd.14259.
［39］	Miteva M, Tosti A. Hair and scalp dermatoscopy［J］. J Am Acad Dermatol, 2012,67（5）:1040⁃1048. doi: 10.1016/j.jaad.2012.02. 013.
［40］	Nguyen B, Tosti A. Alopecia in patients with COVID⁃19: a systematic review and meta⁃analysis［J］. JAAD Int, 2022,7:67⁃77. doi: 10.1016/j.jdin.2022.02.006.
［41］	Bertoli MJ, Sadoughifar R, Schwartz RA, et al. Female pattern hair loss: a comprehensive review［J］. Dermatol Ther, 2020,33（6）:e14055. doi: 10.1111/dth.14055.
［42］	Popescu MN, Berteanu M, Beiu C, et al. Complementary strategies to promote hair regrowth in post⁃COVID⁃19 telogen effluvium［J］. Clin Cosmet Investig Dermatol, 2022,15:735⁃743. doi: 10.2147/CCID.S359052.
［43］	İşlek A, Karaaslan E, Şimşek S, et al. Platelet⁃rich plasma treatment for accelerated androgenetic alopecia pattern hair loss after COVID⁃19 infection: a case series［J］. J Cosmet Dermatol, 2022,21（2）:590⁃594. doi: 10.1111/jocd.14721.

[1]	孙玮蔚陈健儒李舒丽高天文李春英. 白癜风小鼠模型抑郁样行为的观察[J]. 中华皮肤科杂志, 2024, 57(2): 147-154.
[2]	王雨婷姚曼雪周乃慧. 联合微针治疗雄激素性秃发的研究进展[J]. 中华皮肤科杂志, 2024, 57(1): 82-84.
[3]	孙小洁刘毅. 抗雄激素药物治疗皮肤病研究进展[J]. 中华皮肤科杂志, 2023, 56(9): 882-885.
[4]	戴乐恒胡雯张坤杰康晓静. 异鼠李素对H2O2诱导的HaCaT细胞线粒体结构及功能损伤的保护作用研究[J]. 中华皮肤科杂志, 2023, 56(9): 857-861.
[5]	张莉宋秀祖. 血管内皮生长因子在雄激素性脱发中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220240-e20220240.
[6]	邵光辉李煜乾陈启韬朱麒麟朱晶李中明杜旭峰范卫新. 先天性三角形秃发研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220301-e20220301.
[7]	沈雨晴宋秀祖. 紫外线与雄激素性脱发[J]. 中华皮肤科杂志, 2023, 0(2): 20210949-e20210949.
[8]	陈嘉琪张禁唐隽. 新型冠状病毒感染与银屑病之间关系的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220869-e20220869.
[9]	沙雨鸥魏珂璐林尽染刘庆梅倪春雅吴文育. 模式性分布的纤维化性秃发研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220014-e20220014.
[10]	邓维张高磊陈见友张升蒋丽潇刘晓雁苏伟. 61例儿童新型冠状病毒感染的皮肤表现分析[J]. 中华皮肤科杂志, 2023, 56(12): 1154-1157.
[11]	朱鑫宇潘晓媛杨海晶王飞董正邦. 自身免疫性水疱病患者新型冠状病毒感染临床特征[J]. 中华皮肤科杂志, 2023, 56(11): 1023-1027.
[12]	李煜乾朱麒麟朱晶陈启韬李中明许文嵘杜旭峰范卫新. 前额纤维性秃发研究进展[J]. 中华皮肤科杂志, 2023, 56(10): 973-977.
[13]	冯华高英姝李清孙联文. 细胞力学在皮肤科的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 641-644.
[14]	李中明, 许文嵘, 朱麒麟, 朱晶, 李煜乾, 孙杰, 尹莉, 杜旭峰. 瘢痕性女性型脱发1例[J]. 中华皮肤科杂志, 2022, 55(2): 142-145.
[15]	钟连生陈晓艺肖静高海媚纪秀外. 先天性三角形脱发10例临床分析[J]. 中华皮肤科杂志, 2022, 55(12): 1089-1091.

休止期脱发与新型冠状病毒感染的相关性及诊疗研究进展

Associations of telogen effluvium with coronavirus disease 2019 and research progress in its diagnosis and treatment

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

Metrics

本文评价

推荐阅读 10